Doing Life Sciences Deals in 2024
Doing Life Sciences Deals in 2024
Navigating the complexities of life sciences deals in 2024 can be a challenging feat given the current landscape. International Chair of Mintz’s Life Sciences practice Cheryl Reicin, dives into the key factors to consider when structuring licensing, M&A, and asset sales including competitive tension, time of year, multiple business development options, and clear communication.
Learn MoreAwards and Recognition
More from Mintz
Our Offices
-
Boston
t / 617.542.6000 -
Los Angeles
t / 310.586.3200 -
Miami
t / 786.949.6600 -
New York
t / 212.935.3000 -
San Diego
t / 858.314.1500 -
San Francisco
t / 415.432.6000 -
Toronto
t / 647.499.2828 -
Washington, DC
t / 202.434.7300